Determinants of quality of life in adults with epilepsy: a multicenter, cross-sectional study from Germany.
Anti-seizure medication
Depression
Epilepsy
QOLIE-31
Quality of life
Seizure
Journal
Neurological research and practice
ISSN: 2524-3489
Titre abrégé: Neurol Res Pract
Pays: England
ID NLM: 101767802
Informations de publication
Date de publication:
03 Aug 2023
03 Aug 2023
Historique:
received:
15
05
2023
accepted:
04
07
2023
medline:
3
8
2023
pubmed:
3
8
2023
entrez:
2
8
2023
Statut:
epublish
Résumé
Assessment of quality of life (QoL) has become an important indicator for chronic neurological diseases. While these conditions often limit personal independence and autonomy, they are also associated with treatment-related problems and reduced life expectancy. Epilepsy has a tremendous impact on the QoL of patients and their families, which is often underestimated by practitioners. The aim of this work was to identify relevant factors affecting QoL in adults with epilepsy. This cross-sectional, multicenter study was conducted at four specialized epilepsy centers in Germany. Patients diagnosed with epilepsy completed a standardized questionnaire focusing on QoL and aspects of healthcare in epilepsy. Univariate regression analyses and pairwise comparisons were performed to identify variables of decreased QoL represented by the overall Quality of Life in Epilepsy Inventory (QOLIE-31) score. The variables were then considered in a multivariate regression analysis after multicollinearity analysis. Complete datasets for the QOLIE-31 were available for 476 patients (279 [58.6%] female, 197 [41.4%] male, mean age 40.3 years [range 18-83 years]). Multivariate regression analysis revealed significant associations between low QoL and a high score on the Liverpool Adverse Events Profile (LAEP; beta=-0.28, p < 0.001), Hospital Anxiety and Depression Scale - depression subscale (HADS-D; beta=-0.27, p < 0.001), Neurological Disorders Depression Inventory in Epilepsy (NDDI-E; beta=-0.19, p < 0.001), revised Epilepsy Stigma Scale (beta=-0.09, p = 0.027), or Seizure Worry Scale (beta=-0.18, p < 0.001) and high seizure frequency (beta = 0.14, p < 0.001). Epilepsy patients had reduced QoL, with a variety of associated factors. In addition to disease severity, as measured by seizure frequency, the patient's tolerability of anti-seizure medications and the presence of depression, stigma, and worry about new seizures were strongly associated with poor QoL. Diagnosed comorbid depression was underrepresented in the cohort; therefore, therapeutic decisions should always consider individual psychobehavioral and disease-specific aspects. Signs of drug-related adverse events, depression, fear, or stigmatization should be actively sought to ensure that patients receive personalized and optimized treatment. German Clinical Trials Register (DRKS00022024; Universal Trial Number: U1111-1252-5331).
Sections du résumé
BACKGROUND
BACKGROUND
Assessment of quality of life (QoL) has become an important indicator for chronic neurological diseases. While these conditions often limit personal independence and autonomy, they are also associated with treatment-related problems and reduced life expectancy. Epilepsy has a tremendous impact on the QoL of patients and their families, which is often underestimated by practitioners. The aim of this work was to identify relevant factors affecting QoL in adults with epilepsy.
METHODS
METHODS
This cross-sectional, multicenter study was conducted at four specialized epilepsy centers in Germany. Patients diagnosed with epilepsy completed a standardized questionnaire focusing on QoL and aspects of healthcare in epilepsy. Univariate regression analyses and pairwise comparisons were performed to identify variables of decreased QoL represented by the overall Quality of Life in Epilepsy Inventory (QOLIE-31) score. The variables were then considered in a multivariate regression analysis after multicollinearity analysis.
RESULTS
RESULTS
Complete datasets for the QOLIE-31 were available for 476 patients (279 [58.6%] female, 197 [41.4%] male, mean age 40.3 years [range 18-83 years]). Multivariate regression analysis revealed significant associations between low QoL and a high score on the Liverpool Adverse Events Profile (LAEP; beta=-0.28, p < 0.001), Hospital Anxiety and Depression Scale - depression subscale (HADS-D; beta=-0.27, p < 0.001), Neurological Disorders Depression Inventory in Epilepsy (NDDI-E; beta=-0.19, p < 0.001), revised Epilepsy Stigma Scale (beta=-0.09, p = 0.027), or Seizure Worry Scale (beta=-0.18, p < 0.001) and high seizure frequency (beta = 0.14, p < 0.001).
CONCLUSION
CONCLUSIONS
Epilepsy patients had reduced QoL, with a variety of associated factors. In addition to disease severity, as measured by seizure frequency, the patient's tolerability of anti-seizure medications and the presence of depression, stigma, and worry about new seizures were strongly associated with poor QoL. Diagnosed comorbid depression was underrepresented in the cohort; therefore, therapeutic decisions should always consider individual psychobehavioral and disease-specific aspects. Signs of drug-related adverse events, depression, fear, or stigmatization should be actively sought to ensure that patients receive personalized and optimized treatment.
TRIAL REGISTRATION
BACKGROUND
German Clinical Trials Register (DRKS00022024; Universal Trial Number: U1111-1252-5331).
Identifiants
pubmed: 37533112
doi: 10.1186/s42466-023-00265-5
pii: 10.1186/s42466-023-00265-5
pmc: PMC10398956
doi:
Types de publication
Journal Article
Langues
eng
Pagination
41Informations de copyright
© 2023. The Author(s).
Références
Epilepsia. 2022 Feb;63(2):440-450
pubmed: 34931300
Expert Rev Neurother. 2013 Dec;13(12):1355-69
pubmed: 24215282
Eur J Health Econ. 2021 Dec;22(9):1467-1475
pubmed: 34117986
Heliyon. 2022 Oct 14;8(10):e11073
pubmed: 36281370
PLoS Med. 2015 Oct 06;12(10):e1001885
pubmed: 26440803
Chin J Traumatol. 2022 Sep;25(5):272-276
pubmed: 34763994
Epilepsy Behav. 2022 Nov;136:108886
pubmed: 36152384
Curr Neuropharmacol. 2021;19(11):1865-1883
pubmed: 34525933
Health Technol Assess. 1998;2(14):i-iv, 1-74
pubmed: 9812244
Front Neurol. 2021 Nov 30;12:775781
pubmed: 34917019
Eur J Health Econ. 2018 Jul;19(6):861-870
pubmed: 28871490
Epilepsy Behav. 2023 May;142:109179
pubmed: 37058861
Seizure. 2019 Jul;69:92-98
pubmed: 31004927
Telemed J E Health. 2023 Apr;29(4):540-550
pubmed: 35984859
Epilepsy Behav. 2003 Dec;4 Suppl 4:S26-30
pubmed: 14654425
Seizure. 2018 Aug;60:190-197
pubmed: 30031296
Epilepsy Behav. 2011 Jul;21(3):255-60
pubmed: 21576039
J Psychosom Res. 2011 Aug;71(2):74-8
pubmed: 21767686
Epilepsy Behav. 2012 Dec;25(4):485-8
pubmed: 23153711
Front Neurol. 2017 Dec 22;8:712
pubmed: 29312132
Pharmacoeconomics. 2016 Jul;34(7):645-9
pubmed: 26892973
Epilepsy Behav. 2014 May;34:50-4
pubmed: 24681386
Pharmacotherapy. 2023 Jan;43(1):53-84
pubmed: 36484111
Front Neurol. 2022 Apr 25;13:836321
pubmed: 35547374
Epilepsy Behav. 2023 Jan;138:109014
pubmed: 36495800
Gesundheitswesen. 2005 Mar;67(3):173-82
pubmed: 15789280
Lancet. 2007 Oct 20;370(9596):1453-7
pubmed: 18064739
Acta Neurol Scand. 2003 Dec;108(6):428-34
pubmed: 14616296
Front Psychiatry. 2022 Nov 09;13:1000870
pubmed: 36440406
Psychiatr Clin North Am. 2020 Jun;43(2):275-290
pubmed: 32439022
J Psychosom Res. 2002 Feb;52(2):69-77
pubmed: 11832252
Neurol Res Pract. 2022 Sep 22;4(1):44
pubmed: 36131301
Eur J Cardiovasc Nurs. 2004 Dec;3(4):275-7
pubmed: 15572015
Behav Neurol. 2009;21(3):155-63
pubmed: 19996512
Epilepsy Behav. 2017 Oct;75:18-24
pubmed: 28818810
Epileptic Disord. 2021 Dec 1;23(6):803-811
pubmed: 34730519
Epilepsia. 2017 Apr;58(4):512-521
pubmed: 28276062
Epilepsy Behav. 2019 Feb;91:86-89
pubmed: 29752000
Epilepsy Behav. 2022 Feb;127:108554
pubmed: 35063789
Epilepsy Behav. 2023 Jan;138:108982
pubmed: 36459812
Epilepsy Behav. 2023 Jan;138:109005
pubmed: 36516616
Epilepsia. 2007 Mar;48(3):456-63
pubmed: 17284301
Neurol Sci. 2022 Mar;43(3):1955-1964
pubmed: 34524559
Epilepsia. 2011 May;52(5):965-74
pubmed: 21320116
Epilepsia. 2022 Apr;63(4):904-918
pubmed: 35192210
Neurology. 2023 Mar 14;100(11):e1135-e1147
pubmed: 36535780
COPD. 2007 Sep;4(3):263-71
pubmed: 17729071
Epilepsia. 1998 Jan;39(1):81-8
pubmed: 9578017
Epilepsia. 2018 Jul;59(7):1282-1302
pubmed: 29917225
Acta Neurol Scand Suppl. 2012;(194):1-9
pubmed: 23106520
Neurol Res Pract. 2022 Jun 6;4(1):22
pubmed: 35659154
CNS Drugs. 2023 Jun;37(6):531-544
pubmed: 37271775